FAQ

therapeutic autologous dendritic cells

Known as: ADC, autologous dendritic cells 
A population of a type of antigen-presenting cell (APC), the dendritic cell (DC), harvested from a patient and grown in vitro in the presence of… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1950-2017
05010019502016

Related topics

Related topics

6 relations
Antigen SensitizationCytotoxic T-LymphocytesT-Cell Activationautologous dendritic cells/CMV pp65 peptide
(More)

Related mentions per year

Related mentions per year

1951-2018
1960198020002020
therapeutic autologous dendritic cells
Cytotoxic T-Lymphocytes
T-Cell Activation
immunopotentiation
Antigen Sensitization
autologous dendritic cells/CMV pp65 peptide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
UNLABELLED This is a phase II clinical trial investigating the safety and efficacy of intravenous vaccination with mature… (More)
  • table 1
  • table 3
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells…
PURPOSE The aim of this work was to assess immunologic response, disease progression, and post-treatment survival of melanoma… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Measurements of tumor apparent diffusion coefficient (ADC), volume and diameter in assessing the response of patients with… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
PURPOSE The adoptive transfer of in vitro generated tumor antigen-specific cytotoxic T lymphocytes (CTL) provides a promising… (More)
  • table 1
  • figure 1
  • table 2
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors.
The cognate NK-DC interaction in inflamed tissues results in NK cell activation and acquisition of cytotoxicity against immature… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA.
Polyvalent cancer vaccines targeting the entire antigenic spectrum on tumor cells may represent a superior therapeutic strategy… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
We attempted to induce therapeutic immunity against prostate-derived tissues in patients suffering from progressive hormone… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
PURPOSE Provenge (Dendreon Corp, Seattle, WA) is an immunotherapy product consisting of autologous dendritic cells loaded ex vivo… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.
One approach to development of specific cancer immunotherapy relies on the induction of cytotoxic T lymphocytes (CTL) specific… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen.
BACKGROUND Conventional treatment for metastatic prostate cancer have failed to demonstrate curative potential in all patients… (More)
Is this relevant?